| FinnGen provides genetic insights from a well-phenotyped isolated population MI Kurki, J Karjalainen, P Palta, TP Sipilä, K Kristiansson, KM Donner, ... Nature 613 (7944), 508-518, 2023 | 1291 | 2023 |
| Stroke genetics informs drug discovery and risk prediction across ancestries A Mishra, R Malik, T Hachiya, T Jürgenson, S Namba, DC Posner, ... Nature 611 (7934), 115-123, 2022 | 247 | 2022 |
| Polygenic risk scores predict hypertension onset and cardiovascular risk F Vaura, A Kauko, K Suvila, AS Havulinna, N Mars, V Salomaa, FinnGen, ... Hypertension 77 (4), 1119-1127, 2021 | 96 | 2021 |
| Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a Phase I/II Clinical Trial R Virtakoivu, JH Rannikko, M Viitala, F Vaura, A Takeda, T Lönnberg, ... Clinical Cancer Research 27 (15), 4205-4220, 2021 | 36 | 2021 |
| Genetic, molecular, and cellular determinants of sex-specific cardiovascular traits F Vaura, J Palmu, J Aittokallio, A Kauko, T Niiranen Circulation Research 130 (4), 611-631, 2022 | 32 | 2022 |
| Novel biomarkers for diagnosing periprosthetic joint infection from synovial fluid and serum H Keemu, F Vaura, A Maksimow, M Maksimow, A Jokela, M Hollmén, ... JBJS Open Access 6 (2), e20, 2021 | 19 | 2021 |
| Sex differences in genetic risk for hypertension A Kauko, J Aittokallio, F Vaura, H Ji, JE Ebinger, T Niiranen, S Cheng Hypertension 78 (4), 1153-1155, 2021 | 17 | 2021 |
| The genomics of heart failure: design and rationale of the HERMES consortium RT Lumbers, S Shah, H Lin, T Czuba, A Henry, DI Swerdlow, A Mälarstig, ... ESC heart failure 8 (6), 5531-5541, 2021 | 13 | 2021 |
| Polygenic Risk Scores for Predicting Adverse Outcomes After Coronary Revascularization J Aittokallio, A Kauko, F Vaura, V Salomaa, T Kiviniemi, RB Schnabel, ... The American Journal of Cardiology 167, 9-14, 2022 | 8 | 2022 |
| Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results. P Bono, R Virtakoivu, F Vaura, P Jaakkola, S Shetty, A Thibault, ... Journal of Clinical Oncology 38 (15_suppl), 3097-3097, 2020 | 7 | 2020 |
| Associations of polygenic risk scores for preeclampsia and blood pressure with hypertensive disorders of pregnancy J Nurkkala, A Kauko, H Laivuori, T Saarela, JS Tyrmi, F Vaura, S Cheng, ... Journal of Hypertension 41 (3), 380, 2023 | 6 | 2023 |
| Unsupervised hierarchical clustering identifies a metabolically challenged subgroup of hypertensive individuals FC Vaura, VV Salomaa, IM Kantola, R Kaaja, L Lahti, TJ Niiranen The Journal of Clinical Hypertension 22 (9), 1546-1553, 2020 | 5 | 2020 |
| Multi-Trait Genetic Analysis Reveals Clinically Interpretable Hypertension Subtypes F Vaura, H Kim, MS Udler, FinnGen*, V Salomaa, L Lahti, T Niiranen Circulation: Genomic and Precision Medicine 15 (4), e003583, 2022 | 2 | 2022 |
| Verenpainetaudin geneettinen tausta F Vaura, T Niiranen | 1 | 2022 |
